مباشر

Clinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk Endpoints NewsEli Lilly's claims data deadline may kick off new 340B fight Clinical OMICsFirst Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results AgilentAgilent Showcases Integrated Mass Spectrometry and Chromatography Solutions at ASMS 2026 - the-scientist.com Endpoints NewsGrace Science says FDA bottleneck jeopardizes rare disease therapy Clinical OMICsDigital Pathology and the NHS: Overcoming Barriers to a More Connected Future FierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EY FierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market BioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studies Endpoints NewsA different approach to lowering healthcare costs CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity Clinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics Diagnostics

BioWorld ٩ يونيو ٢٠٢٦

Pheon Therapeutics discovers new CDCP1-targeting ADCs

Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, th...

Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer.